Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice

被引:0
作者
Sarah A. Davie
Jeannie E. Maglione
Cathyryne K. Manner
Dmitri Young
Robert D. Cardiff
Carol L. MacLeod
Lesley G. Ellies
机构
[1] University of California,Moores UCSD Cancer Center, Department of Medicine
[2] San Diego,Center for Comparative Medicine
[3] University of California,undefined
[4] Davis,undefined
来源
Transgenic Research | 2007年 / 16卷
关键词
FVB/NJ; C57Bl/6J; Strain; iNOS; Breast; Cancer; Polyomavirus middle T antigen; Mouse;
D O I
暂无
中图分类号
学科分类号
摘要
The ability to genetically manipulate mice has led to rapid progress in our understanding of the roles of different gene products in human disease. Transgenic mice have often been created in the FVB/NJ (FVB) strain due to its high fecundity, while gene-targeted mice have been developed in the 129/SvJ-C57Bl/6J strains due to the capacity of 129/SvJ embryonic stem cells to facilitate germline transmission. Gene-targeted mice are commonly backcrossed into the C57Bl/6J (B6) background for comparison with existing data. Genetic modifiers have been shown to modulate mammary tumor latency in mouse models of breast cancer and it is commonly known that the FVB strain is susceptible to mammary tumors while the B6 strain is more resistant. Since gene-targeted mice in the B6 background are frequently bred into the polyomavirus middle T (PyMT) mouse model of breast cancer in the FVB strain, we have sought to understand the impact of the different genetic backgrounds on the resulting phenotype. We bred mice deficient in the inducible nitric oxide synthase (iNOS) until they were congenic in the PyMT model in the FVB and B6 strains. Our results reveal that the large difference in mean tumor latencies in the two backgrounds of 53 and 92 days respectively affect the ability to discern smaller differences in latency due to the Nos2 genetic mutation. Furthermore, the longer latency in the B6 strain enables a more detailed analysis of tumor formation indicating that individual tumor development is not stoichastic, but is initiated in the #1 glands and proceeds in early and late phases. NO production affects tumors that develop early suggesting an association of iNOS-induced NO with a more aggressive tumor phenotype, consistent with human clinical data positively correlating iNOS expression with breast cancer progression. An examination of lung metastases, which are significantly reduced in PyMT/iNOS−/− mice compared with PyMT/iNOS+/+ mice only in the B6 background, is concordant with these findings. Our data suggest that PyMT in the B6 background provides a useful model for the study of inflammation-induced breast cancer.
引用
收藏
页码:193 / 201
页数:8
相关论文
共 184 条
[1]  
Boras-Granic K(2006)Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland Dev Biol 295 219-231
[2]  
Chang H(2003)Mouse models of human breast cancer Comp Med 53 250-253
[3]  
Grosschedl R(1999)The comparative pathology of human and mouse mammary glands J Mammary Gland Biol Neoplasia 4 105-122
[4]  
Hamel PA(2004)Interactions between FGF and Wnt signals and Tbx3 gene expression in mammary gland initiation in mouse embryos J Anat 205 1-13
[5]  
Cardiff RD(2003)Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase Int J Cancer 106 1-7
[6]  
Cardiff RD(2003)Interrogating mouse mammary cancer models: insights from gene expression profiling J Mammary Gland Biol Neoplasia 8 321-334
[7]  
Wellings SR(1992)Polyoma tumorigenesis in mice: evidence for dominant resistance and dominant susceptibility genes of the host Virology 191 724-731
[8]  
Eblaghie MC(1992)Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease Mol Cell Biol 12 954-961
[9]  
Song SJ(1994)Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice Genes Dev 8 23-32
[10]  
Kim JY(2005)Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade Oncol Rep 13 559-583